News and Trends 9 Feb 2017 Alma Bio Therapeutics is Aiming to Revolutionize the Treatment of IBD A new immune modulator to treat Inflammatory Bowel Diseases (IBD) is the lead asset in development at Alma Bio Therapeutics. We had the opportunity to meet up with the company’s co-founder and CEO, Binah Baum, to hear more about their fresh approach to treating IBD and other autoimmune diseases. Binah Baum, another female leader in […] February 9, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2017 German Biotech gets Seed Funding to Repurpose Cancer Drugs for the Flu Atriva Therapeutics has received seed funding to advance the development of a better therapy for influenza in patients at high risk. Atriva Therapeutics was founded in Tübingen, Germany in 2015 with a quite particular aim: repurposing cancer drugs to treat influenza. Two private investors, the Dutch Stichting Participatie Atriva and the German High-Tech Gründerfonds (HTGF) have contributed with […] February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 8 Feb 2017 The First Stroke Drug in Decades? French Biotech gets closer to the Clinic Acticor Biotech has raised €1.5M from CapDecisif Management, which will help its candidate for acute ischemic stroke enter Phase I trials. Acticor Biotech is a spin-off from the French National Institute of Health and Medical Research (Inserm) focusing on treating the acute phase of ischemic stroke, which occurs within the first few hours. The French VC firm CapDecisif Management has seen promise in […] February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 8 Feb 2017 The FDA lays down Laws of Interchangeability: New Era for Biosimilars? The new guidelines from the FDA on interchangeability may bring the US biosimilar market up to speed and a new opportunity for European companies. Though the US has long been seen as the most promising market for biosimilars due to the size of the market and high drug prices driving an interest in more affordable options, […] February 8, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2017 Cannabinoid Drug Prolongs the Life of Brain Tumor Patients in Phase II Trials GW Pharmaceuticals announced Phase II results for a cannabinoid drug combination with the potential to increase life expectancy in patients with an aggressive form of brain cancer. GW Pharmaceuticals, one of the coolest biotechs in Cambridge, is developing cannabinoid drugs. Its lead candidate, Epidiolex, could reach the market soon and help treat drug-resistant forms of […] February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2017 British Synbio’s Llama Antibodies recruited for Cancer T-Cell Therapy Isogenica has licensed its synthetic llama antibody library to Maverick Therapeutics, which develops cancer T-cell therapies designed to reduce side effects. Isogenica is a synthetic biology company near Cambridge that develops libraries of therapeutic antibodies. The biotech has granted US-based Maverick Therapeutics licenses to its llamdA VHH antibody library for the discovery, development and commercialization of […] February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2017 Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials of its lead candidate foliglurax in Parkinson’s. An international team of top European biotech investors has participated in Prexton Therapeutics’ latest financing round. The €29M Series B round was co-led by the Dutch Forbion and the Irish Seroba Life Sciences, […] February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2017 French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial Innate Pharma’s checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow to the company’s stock. When the stock market opened this morning, Innate Pharma‘s stock went down by almost 25%. The company had just announced the results of a Phase II trial that failed to prove its […] February 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 6 Feb 2017 “We want to be the Worldwide Leader in Microbiota” Biotech entrepreneur Hervé Affagard, CEO of MaaT Pharma, tells the story behind the success of his young microbiome company. Hervé Affagard is the CEO and co-founder of a company with an ambitious goal: become the global leader in treating the gut microbiota. Founded in 2014 and based in Lyon, MaaT pharma wants to employ fecal transplants to treat […] February 6, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 4 Feb 2017 This PhD-Carrying Musician Tells the Story of Life through Music & Video Max Cooper bridges the age-old divide between science and art with a transfixing blend of glitchy electronica, classical music and haunting vocals. I was lucky enough to catch Max Cooper live in Dublin last weekend, during his tour to showcase his latest album, Emergence. Inspired by natural processes and the laws underlying them, Emergence is a tour-de-force of […] February 4, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2017 Could GM Insects impact the international trade of Organic Food? Genetically modified insects are released to control the spread of diseases and crop pests, but the logistics may not be so simple: these little creatures could jam global food exports, particularly to more GM-averse Europe. What happens when genetically engineered insects develop on vegetable farms? Two researchers, from the Max Planck Institue for Evolutionary Biology in […] February 3, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 2 Feb 2017 Galapagos kicks off a Phase IIa trial for Cystic Fibrosis After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […] February 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email